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Familial Pityriasis Rubra Pilaris Is
Caused by Mutations in CARD14
Dana Fuchs-Telem,1,2 Ofer Sarig,1 Maurice A.M. van Steensel,3,4 Ofer Isakov,5 Shirli Israeli,1,2
Janna Nousbeck,1 Katharina Richard,6,7 Veronique Winnepenninckx,4,8 Marigje Vernooij,3
Noam Shomron,5 Jouni Uitto,7 Philip Fleckman,9 Gabriele Richard,10 and Eli Sprecher1,2,*
Pityriasis rubra pilaris (PRP) is a papulosquamous disorder phenotypically related to psoriasis. The disease has been occasionally shown
to be inherited in an autosomal-dominant fashion. To identify the genetic cause of familial PRP, we ascertained four unrelated families
affected by autosomal-dominant PRP. We initially mapped PRP to 17q25.3, a region overlapping with psoriasis susceptibility locus 2
(PSORS2 [MIM 602723]). Using a combination of linkage analysis followed by targeted whole-exome sequencing and candidate-gene
screening, we identified three different heterozygousmutations inCARD14, which encodes caspase recruitment domain family, member
14. CARD14 was found to be specifically expressed in the skin. CARD14 is a known activator of nuclear factor kappa B signaling, which
has been implicated in inflammatory disorders. Accordingly, CARD14 levels were increased, and p65 was found to be activated in the
skin of PRP-affected individuals. The present data demonstrate that autosomal-dominant PRP is allelic to familial psoriasis, which
was recently shown to also be caused by mutations in CARD14.Pityriasis rubra pilaris (PRP [MIM 173200]) is an
uncommon skin disorder of unknown etiology and is
characterized by the appearance of keratotic follicular
papules, well-demarcated salmon-colored erythematous
plaques covered with fine powdery scales interspersed
with distinct islands of uninvolved skin, and palmoplantar
keratoderma (thickening of the skin of the palms and
soles). PRP occurs equally in men and women and is
seen in about 1 in 5,000 individuals diagnosed with skin
disease in Great Britain.1 Although most cases of PRP are
simplex cases, up to 6.5% of all PRP-affected individuals
report a positive family history.1–3 Those rare familial cases
demonstrate autosomal-dominant inheritance with an
early age of onset, incomplete penetrance, and variable
expression.3–8
Griffiths classified PRP into five types on the basis of age
of onset, clinical features, and prognosis; these types are
classic adult type I, atypical adult type II, classic juvenile
type III, circumscribed juvenile type IV, and atypical
juvenile type V.9,10 More recently, a type VI PRP, or human
immunodeficiency virus (HIV)-associated PRP, has been
described.11–14 Familial PRP belongs to the type V group,
which accounts for about 5% of all cases.1,8,9 It is usually
present at birth or appears during the first years of life
and runs a chronic course. It is characterized by prominent
follicular hyperkeratosis, diffuse palmoplantar kerato-
derma, and erythema8,9 Response to treatment is disap-
pointing. Modest results have been reported for retinoids,
cyclosporine, and, lately, TNF-alpha-blocking agents.1Department of Dermatology, Tel Aviv SouraskyMedical Center, Tel Aviv 64239
Faculty of Medicine, Tel Aviv University, Ramat Aviv 69978, Israel; 3Departme
The Netherlands; 4GROW School for Oncology and Developmental Biology,
5Department of Cell and Developmental Biology, Sackler Faculty of Medicine
and Immunology, University of Maryland School of Medicine, Baltimore, MD
Thomas Jefferson University, Philadelphia, PA 19107, USA; 8Department of
Netherlands; 9Division of Dermatology, University of Washington, Seattle, W
*Correspondence: elisp@tasmc.health.gov.il
DOI 10.1016/j.ajhg.2012.05.010. 2012 by The American Society of Human
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etiology was proposed on the basis of clinical observa-
tions15 and the known association between PRP and HIV
infection.11–14 PRP has also been reported to be associated
with defective vitamin A metabolism or vitamin A defi-
ciency.1 However, on the basis of clinical and pathological
features, it is now classified as a papulosquamous disease,
which, like psoriasis, is thought to result from abnormal
activation of inflammatory pathways.16 Although PRP
and psoriasis might manifest with overlapping features,
they are distinguishable on clinical and histopathological
grounds. PRP is characterized by prominent involvement
of the face, classical islands of sparing over the trunk,
follicular hyperkeratosis, distinctive diffuse red-orange
palmoplantar keratoderma, and the absence of psoriasis-
associatednail changes. Althoughpsoriasis is typically asso-
ciated with hypogranulosis, intraepidermal neutrophilic
infiltration culminating with the formation of Munro
microabscesses, elongation of the rete ridges, and marked
vascular dilation in the papillary dermis,1,17–19 PRP features
include alternating parakeratosis and orthokeratosis,
hypergranulosis, broad thickening of the rete ridges, thick
suprapapillary plates, follicular hyperkeratosis, lack of
neutrophilic infiltration, and limited vascular dilatation.20
In the present study, we demonstrate that familial PRP
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Figure 1. Clinical and Histopathological Features of PRP-Affected Families
Note the conspicuous presence of widespread erythematous plaques coalescing into large areas containing islands of normal-appearing
skin, follicular plugging, and palmoplantar keratoderma. In all cases, histopathology demonstrates alternating parakeratosis and ortho-
keratosis, acanthosis, and a mononuclear dermal infiltrate.We assessed four families affected by dominant PRP. In
familyD,weonlyhad access toDNA from twoaffected indi-
viduals. All participants provided their written informed
consent to participate to this study in accordance with
protocols reviewed and approved by institutional review
boards at each participating center. A diagnosis of PRP was
based on the presence of characteristic clinical and histo-
pathological features (Figure 1 and Table 1). All affected
individuals showedwell-demarcated erythematous plaques
coalescing into large areas interspersed with islands of
normal skin, follicular papules or accentuation, palmoplan-
tar keratoderma, and a lack of psoriasis-associated nail
changes.Histopathology of skin lesions showed alternating
orthokeratosis and parakeratosis, acanthosis with broad-
ening of the rete ridges, follicular plugging, lymphocytic
infiltrate in the dermis, and a lack of neutrophils in the
epidermis. Age of onset varied from 4 to 36 months of
age. DNA from members of family A was extracted from
saliva samples with the use of an Oragene DNA kit (DNA
Genotek, Kanata, Ontario, Canada), DNA from members
of families B and C was extracted from lymphoblast cell
lines, and DNA from two affected individuals of family D
was extracted from peripheral-blood lymphocytes.
We genotyped all availablemembers of family A by using
the Illumina Human Linkage 12 chip comprising 6,000164 The American Journal of Human Genetics 91, 163–170, July 13, 2tagged SNPs distributed across the genome. Two hundred
nanograms of DNA was hybridized according to the Infin-
ium II assay (Illumina, San Diego, CA) and scannedwith an
Illumina BeadArray reader. The scanned images were
imported into BeadStudio 3.1.3.0 (Illumina) for extraction
and quality control and produced an average call rate of
99.9%. Multipoint linkage analysis with the Allegro
software23 implemented in the easyLinkage package24
generated a LOD score of 2.79 at marker rs11150586 in
the centrosomal region of chromosome 16 and a LOD
score of 2.50 at marker rs938283 on chromosome 17
(Figure 2A). Fine mapping of the two regions of interest
in families A, B, and C was performed with polymorphic
microsatellite markers that were selected from the National
Center for Biotechnology Information (NCBI) database.
Microsatellite analysis was performed on an automated
sequencer (ABI 3100 Genetic Analyzer; PE Applied Bio-
systems, Foster City, CA, USA) with sequence-specific
forward and reverse primers and a universal fluorescently
labeled M13 primer as previously reported.25 Allele sizes
were determined with GeneMapper v.4.0 software. Haplo-
type analysis ruled out linkage to the chromosome 16
region (Figure S1, available online). All three families were
found to map to 17q25.3, generating a combined LOD
score of 3.73 (analysis was performed with the Superlink012
Table 1. Clinical and Pathological Features
Family A Family B Family C Family D
Age of onset (months) 4 9 8 36
Face involvement þ þ þ þ
Scalp involvement þ   
Islands of normal skin þ þ þ þ
PPK mild erythematous with scale
but no thickening
accentuate skin markings
with a beaded appearance
but not thickened
mild
Nail changes none none thickened with onychorrhexis þ/
Alternating orthokeratosis and
parakeratosis
þ þ þ þ
Lymphocytic infiltrate on
pathology
mild dermal lymphocytic mild dermal lymphocytic mild dermal lymphocytic mild dermal lymphocytic
Follicular plugging þ þ þ þsoftware;26 the LOD scores calculated for families A, B,
and C were, respectively, 1.9366, 1.1950, and 0.5977).
Critical recombination events in family A members II-2
and III-3 set the disease interval between markers
D17S722 and D17S668 (Figure 2B). Of note, two obligatory
carriers (I-3 and II-4) were completely asymptomatic
despite the fact that they were carriers of the disease-
associated haplotype.
The 5 Mb candidate region was found to contain 118
genes. To identify the gene harboring PRP-causing muta-
tions, we performed targeted capture (for individuals II-2,
II-4, II-5, and III-4 from family A) and exome capture (for
individuals II-2 and III-4 from family A). The DNA samples
used for targeted capture were prepared with paired-end
adapters according to the manufacturer’s (Illumina) guide-
lines. After quality control, the library was captured on
a custom repeat-masked 244K Agilent SureSelect solid
array (Agilent, Santa Clara, CA). Next-generation sequenc-
ing was performed on an Illumina Genome Analyzer IIx.
The resulting reads were aligned to the UCSC human refer-
ence sequence (hg19/GRCh37) with the use of the Burrows
Wheeler aligner (BWA)27 and SoapSNP for SNP calling.
Because of the low coverage obtained by the targeted
capture (Table S1), we used two different approaches for
exome sequencing. First, a genomic library of the DNA
sample from III-4 was prepared according to the Agilent
standard protocol for SOLiD library preparation. The
library was captured with the SureSelect Human All Exon
kit (Agilent). Next-generation sequencing was carried out
on the SOLiD V3 system (Applied Biosystems). The result-
ing reads were aligned to the hg19 reference sequence with
Bioscope 1.2 (Applied Biosystems) and the BWA. SNP call-
ing was performed with Bioscope 1.2 and SAMTOOLS.28
Second, a genomic library of the DNA sample from II-2
was prepared with paired-end adapters according to Illumi-
na’s protocol, and exome enrichment was achieved with
a NimbleGen SeqCap EZ Human Exome Library v.2.0
(Roche NimbleGen, Madison, WI, USA). The sample wasThe Amsequenced on an Illumina HiSeq2000 system.We analyzed
all data for quality, exome coverage, and exome-wide SNPs
and indels by using the platform provided by DNAnexus
(DNAnexus, Mountain View, CA, USA).
A total of 436 sequence variants were identified in the
candidate region. After having filtered out 409 variants
that were found to correspond to common variants in
public databases (NCBI, UCSC, and the 1000 Genomes
Project), we verified all putative mutations by Sanger
sequencing. Only one of the sequence variants was found
to cosegregate with the disease phenotype in family A;
this variant was c.290G>C (p.Gly97Ala) in TMEM105
(RefSeq accession number NM_178520.3), the gene encod-
ing the transmembrane protein 105. Direct sequencing of
this gene in families B–D revealed additional cosegregating
sequence alterations in TMEM105. In family B, we identi-
fied a 7 bp deletion (c.58delGGGCCCA) in the 50 UTRof the
gene, whereas in family D, we identified c.2726C>G in the
30 UTR of the gene. These variations have recently been re-
ported to represent very rarepolymorphisms (rs147929646,
rs137864500, and rs182343738, respectively).
Because next-generation-sequencing efforts did not lead
to the identification of the proximal cause of PRP in the
affected four families, we scrutinized all exons that were
within the disease interval and that had insufficient
coverage (<103) by either exome or targeted sequencing.
All together, 17.4% and 6% of exons from individuals
III-4 and II-2, respectively, were defined as candidates for
resequencing by Sanger technology (Table S1). We priori-
tized those exons by functional relevance to the pathogen-
esis of PRP, and we initially sequenced exons of genes
encoding regulators of epithelial differentiation or media-
tors of inflammation. This strategy finally revealed hetero-
zygous mutations in CARD14 (RefSeq NM_024110.4) in
all families (Figure 3A).Mutations c.467T>C (p.Leu156Pro)
and c.412_414delGAG (p.Glu138del) were found in exon 4
and alter highly conserved amino acids (Figure 3B). Muta-
tion c.349þ1G>A abolishes the consensus donor spliceerican Journal of Human Genetics 91, 163–170, July 13, 2012 165
Figure 2. Linkage, Haplotype, and PCR-RFLP Analysis
(A) Multipoint LOD-score analysis was performed with the Allegro software23 implemented in the easyLinkage package24 and produced
an estimated penetrance of 90%. LOD scores are plotted against all SNP markers distributed across the genome.
(B) Haplotype analysis with polymorphic markers across chromosomal region 17q25.3 reveals a heterozygous 5 Mb interval between
markers D17S722 and D17S668; this interval is uniquely shared by affected individuals or obligatory carriers. PCR restriction frag-
ment-length polymorphism (PCR-RFLP) analysis, shown below each pedigree, confirmed segregation of the mutations in the families.
Mutation c.467T>C in CARD14 abolishes a recognition site for AlwnNI; thus, healthy individuals display 191 bp and 128 bp fragments,
whereas affected heterozygous individuals also show a 319 bp fragment (families A and B). Mutation c.412_414delGAG in CARD14
disrupts a recognition site for EcoNI; thus, healthy individuals display 187 bp and 132 bp fragments, whereas affected heterozygous indi-
viduals also show a 319 bp fragment (family C).site in intron 3 of CARD14 and generates an aberrant splice
variant as a result of the use of a cryptic splice site, causing
the insertion of an extra 66 bp originating from intron 3
(Figure 3C). We confirmed segregation of the mutation
with the disease phenotype throughout families A, B, and
C by using PCR restriction fragment-length polymorphism
(PCR-RFLP). PCR fragments, encompassing exons 3 or 4,
were PCR amplified and digested with AlwnNI, EcoNI, or
AciI (New England Biolabs, Ipswich, MA) at 37C for
16 hr. We also excluded all mutations from a panel of
100 healthy population-matched control individuals
(200 alleles). In addition, none of themutationswere found
in major public databases (NCBI or UCSC), including in
a total of more than 8,200 individual sequences deposited
in the 1000 Genomes Project and in the National Heart,
Lung, and Blood Institute (NHLBI) Grand Opportunity
Exome Sequencing Project. Of note, mutation c.467T>C
was detected in two families (families A and B) on the back-
ground of distinct haplotypes (not shown), suggesting
spontaneously recurrent mutational events rather than a
founder effect.
To assess the relevance of our findings to the skin
pathology seen in PRP, we assessed CARD14 tissue-specific
expression. cDNA was synthesized from 500 ng of Human
Total RNA Survey Panel (Ambion, Austin, TX). CARD14
cDNA PCR amplification was carried out with the Fast166 The American Journal of Human Genetics 91, 163–170, July 13, 2SYBR Green Master Mix on a StepOne Real-Time PCR
System (Applied Biosystems) with gene-specific intron-
crossing oligonucleotide pairs (forward primer 50-AGGCA
GGTGTTCGAGCTG-30 and reverse primer 50-GGTCCTG
GCTTCCTGCTT-30). In line with previous semiquantita-
tive RT-PCR experiments21 and microarray data,29 we
detected a high level of CARD14 expression in mucosal
tissue. Comparative quantitative analysis of CARD14 ex-
pression in 22 different tissues showed that CARD14 RNA
levels are five times higher in the skin than in any other
human tissue (Figure 4).
To assess the functional consequences of the mutations
detected in PRP-affected individuals, we stained skin
biopsies from these individuals with a CARD14 antibody
(Novus Biologicals, Littleton, CO). As shown in Figure 5B,
CARD14 immunostaining was found to be stronger in PRP-
affected skin than in normal skin. In addition, whereas
CARD14 staining was mostly restricted to the lower layers
of the normal epidermis, CARD14 was localized up to the
granular layers in PRP-affected skin. In addition, because
CARD14 has been shown to modulate the activity of
NF-kB, which was previously shown to be involved in
inflammatory skin diseases,30 we stained PRP-affected
and normal control-derived skin biopsies with a mono-
clonal antibody that recognizes an epitope overlapping
the nuclear localization signal of the p65 subunit012
Figure 3. Mutation Analysis
(A) Direct sequencing of CARD14 revealed three heterozygous mutations: c.467T>C in families A and B, c.412_414delGAG in family C,
and c.349þ1G>A in family D.
(B) Analysis of the CARD14 region encompassing mutant residues p.Glu138del and p.Leu156 (both in red) demonstrates conservation
across species.
(C) Sequence analysis of RT-PCR products generated with RNA extracted from a skin biopsy of an affected individual of family D revealed
two splice variants, which, through sequencing, were found to correspond to the wild-type cDNA sequence and to an aberrant splice
variant containing an extra 66 bp originating from intron 3.(Millipore, Billerica, MA). In addition to the stronger inten-
sity of the staining found in PRP-affected skin (Figure 5D),
we also observed a significant difference in the percentage
of activated p65-positive suprabasal cells in PRP-affected
skin as compared with normal skin (Figure 5E). These
results are in agreement with in vitro data showing that
highly similar CARD14 mutations recently implicated in
the pathogenesis of familial psoriasis result in NF-kB acti-
vation.31 To further assess the effect of the CARD14 muta-
tions on NF-kB activity, we studied the expression of three
known NF-kB target genes in PRP-affected skin (Figure 5F).
We performed PCR amplification of CCL20 (MIM 601960),
IL1B (MIM 147720), and NOS2 (MIM 163731) cDNA on
a StepOne Real-Time PCR System (Applied Biosystems)The Amby using the Fast SYBR Green Master Mix, cDNA derived
from skin biopsies obtained from an affected member of
family D and from a healthy individual, and gene-specific
intron-crossing oligonucleotide pairs (primer pairs for
CCL20, IL1B, and NOS2 were 50-CGAATCAGAAGCAAG
CAA-30 and 50-AGCATTGATGTCACAGCCTTCAT-30, 50-CA
TTGCTCAAGTGTCTGAAGCA-30 and 50-CTGGAAGGAGC
ACTTCATCTGTT-3, and 50-CTGCAGACACGTGCGTTAC
TC-30 and 50- GAAGTCGTGCTTGCCATCACT-30, respec-
tively). Compared with normal skin, the PRP-affected
skin showed upregulation of all three genes (Figure 5F).
In the present study, we provide evidence indicating
that mutations in CARD14 cause familial PRP. The known
role of CARD14 in the regulation of inflammatoryerican Journal of Human Genetics 91, 163–170, July 13, 2012 167
Figure 4. CARD14 Expression Analysis
Results are provided as a percentage of CARD14 expression relative
to its level of expression in skin after normalization to ACTB.processes,29,32 the high expression of CARD14 in the skin,
and the fact that NF-kB is activated in PRP-affected skin are
also supportive of a role for this protein in the patho-
genesis of PRP. Of note, the fact that penetrance was
incomplete in some of the families we studied suggests a
possible role for additional modifying traits, epigenetic
factors, or environmental elements in determining the
phenotypic expression of the causative mutations.
CARD14, CARD10, and CARD11, also known as CARD-
and membrane-associated guanylate kinase-like domain-
containing proteins, share a high degree of sequence and
structural homology.21,22,29 All three proteins contain
a CARD domain, coiled-coil (C-C) domain, SH3 domain,
PDZ domain, and GuK domain;21,22 however, they exhibit
a distinct tissue-distribution pattern. CARD10 is found in
a broad range of tissues and not in hematopoietic cells,
whereas CARD11 is present in hematopoietic tissues.29
CARD14 was previously found to be abundant in placental
and mucosal tissues.22,29 Here, we demonstrate its high
level of expression in the skin.
Recently, pathogenicmutations located in the vicinity of
the mutations reported in the present study were found to
underlie both familial and nonfamilial cases of psori-
asis.31,33 Psoriasis and PRP have been considered over the
years as two separate entities both clinically and histologi-
cally.18 PRP and psoriasis have traditionally been differen-168 The American Journal of Human Genetics 91, 163–170, July 13, 2tiated on the basis of the distinctive clinical and histopath-
ological features reviewed above as well as the inconsistent
response of PRP to UVB phototherapy. The present data
suggest that the two diseases, at least in their familial
forms, share a common pathophysiology, which in turn
might bear important implications for the therapeutic
approach to PRP.
CARD14 binds to B cell lymphoma 10 (BCL10) through
a CARD-CARD interaction and also functions as an
upstream regulator of NF-kB signaling and thereby protects
cells from apoptosis induced by different stimuli.21,22
All three PRP-causing mutations identified in this study
alter the structure of the coiled-coil domain of CARD14,
which was found to be associated with NF-kB activation.
The function of the coiled-coil domain of CARD14 re-
mains to be fully delineated. Of note, mice carrying an
ethylnitrosourea-induced point mutation in the coiled-
coil domain of CARD11 showed defects in humoral
immune responses, defective B cell activation by antigen
receptors, and Tcell costimulation by CD28 and developed
a skin disorder similar to atopic dermatitis with elevated
levels of IgE.34 This suggests that the coiled-coil domain
is important for the regulation of CARD activation.
NF-kB has been shown to promote keratinocyte viability
during differentiation.35 Mice displaying constitutive acti-
vation of NF-kB develop a generalized skin disorder histo-
logically featuring epidermal hyperplasia, hyperkeratosis,
parakeratosis, hypogranulosis, T cell infiltration, and the
formation of microabscesses. These data are in line with
the possibility that the CARD14 mutations identified in
our study modulate the NF-kB signaling pathway within
keratinocytes and ultimately lead to aberrant immunolog-
ical activation. It is therefore of interest that anti-TNF-
alpha treatment has been shown to be of therapeutic
benefit for PRP, including familial PRP,8 and that TNF-alpha
antagonists are known to target NF-kB signaling,36 and
response to these drugs is even in part determined by poly-
morphisms in genes belonging to the NF-kB pathway36
Moreover, an abnormal response to microbial agents has
been proposed to contribute to the pathogenesis of both
psoriasis and PRP.20,37 Other CARD domain proteins,
notably NOD2 (CARD15), are involved in the response to
bacteria. Colitis-associated CARD15 mutations cause a
decreased response to bacterial cell-wall components. It is
tempting to speculate that PRP might be akin to colitis in
that respect and might, in part, result from altered host-
microbiome interactions.
In conclusion, a century after familial PRP was originally
described,38 we demonstrate in the present study that this
disorder results from mutations in CARD14, which regu-
lates NF-kB signaling and which is strongly expressed in
the skin.Supplemental Data
Supplemental Data include one figure and one table and can be
found with this article online at http://www.cell.com/AJHG.012
Figure 5. Elevated CARD14 Levels and
NF-kB Hyperactivation in the Epidermis
of PRP-Affected Individuals
Skin-biopsy sections obtained from a
person with PRP (B and D) and from a
healthy individual (A and C) were stained
with antibodies directed against CARD14
(A and B) or an activated p65 subunit of
NF-kB (C and D).
(E) The percentage of activated-p65-
positive nuclei was determined in the
suprabasal layers of the epidermis. The
percentage of positive nuclei was signifi-
cantly higher in the affected individual
(c ¼ 33.2, p ¼ 8.5 3 109).
(F) Expression levels of three NFkB target
genes were determined with quantitative
RT-PCR and cDNA derived from a skin
biopsy obtained from a member of family
D. The results were normalized to ACTB
(MIM 102630) expression and are ex-
pressed as a percentage of the control.
Data shown represent mean values of
triplicates 5 SD (*p < 0.05,**p < 0.01 by
a Student’s t test).Acknowledgments
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